Helus Pharma Inc.
HELP Nasdaq Pharmaceutical Preparations Financials FY2025–FY2026
Last close · Oct 23, 2026
$10.19
3.0%What Helus Pharma Inc. does
No business description yet.
- Legal name
- Helus Pharma Inc.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 40-F · Jun 29, 2026
- Accession · CIK
- 0001833141-26-000046
0001833141
Revenue and margins
Helus Pharma Inc. had — of revenue in fiscal 2026.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2026, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Helus Pharma Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 72.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Helus Pharma Inc. can carry it.
| Fiscal year end | FY25 | FY26 |
|---|---|---|
| Cash and short-term investments | $93.9M | $157M |
| Current ratio | 7.7x | 9.5x |
| Quick ratio | 7.7x | 9.5x |
| Total assets | $180M | $251M |
| Total liabilities | $14.9M | $19.4M |
| Shareholders' equity | $165M | $232M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY25 | FY26 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | — |
| F-score | — / 3 | — / 6 |
| Accruals ratio | −5.2% | −6.8% |
| Altman Z'' | — | — |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY25 | FY26 |
|---|---|---|
| Income statement | ||
| Research and development | $39.2M | $86.6M |
| Income tax | $0.0M | $0.0M |
| Net income | −$81.6M | −$148M |
| Diluted EPS | −$4.04 | −$4.25 |
| Diluted shares | 0.02B | 0.03B |
| Cash flow | ||
| Cash from operations | −$72.3M | −$133M |
| Depreciation and amortization | $0.3M | $0.1M |
| Stock-based compensation | $31.3M | $10.9M |
| Balance sheet | ||
| Cash and short-term investments | $93.9M | $157M |
| Current assets | $115M | $185M |
| Current liabilities | $14.9M | $19.4M |
| Property and equipment, net | $0.1M | $0.2M |
| Goodwill | $35.8M | $36.2M |
| Intangible assets | $28.5M | $30.2M |
| Total assets | $180M | $251M |
| Total liabilities | $14.9M | $19.4M |
| Shareholders' equity | $165M | $232M |
| Returns | ||
| Return on equity | −49.5% | −74.6% |
| Return on assets | −45.4% | −68.7% |
| Return on tangible equity | −81.1% | −89.5% |
| Growth | ||
| Share count change | — | 72.1% |
| Financial health | ||
| Current ratio | 7.7x | 9.5x |
| Quick ratio | 7.7x | 9.5x |
| Quality scores | ||
| Accruals ratio | −5.2% | −6.8% |
Source: SEC EDGAR XBRL filings (CIK 0001833141). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.